Why MannKind Stock Tumbled on Thursday

MrDecoder · 2026-02-27T08:34:54+00:00

MannKind's stock fell over 7% after a mixed earnings report showing a 46% revenue increase but a decline in profit. Despite heightened costs from the acquisition of Furoscix, the company's strong pipeline suggests potential value for investors.

MrDecoder

2026-02-27 08:34:54

Abstract generation in progress

MannKind (MNKD 8.14%) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech’s equity, as they clearly felt its latest earnings release to be lacking – despite a significant top-line beat. MannKind closed the day down more than 7% in value.

An unkind investor reaction

MannKind released its fourth-quarter and full-year 2025 results before market open, reporting that revenue grew 46% year over year to just under $112 million. However, that period’s tally includes almost $22.9 million from sales of edema treatment Furoscix. This became part of the company’s portfolio following the October 2025 acquisition of the drug’s developer, scPharmaceuticals.

Image source: Getty Images.

On the bottom line, net income not in accordance with generally accepted accounting principles eroded to just over $1.5 million ($0.01 per share), from the year-ago profit of almost $23 million.

That meant a mixed quarter for MannKind, as it narrowly missed the average analyst estimate of $0.02 per share for non-GAAP (adjusted) profitability but trounced the consensus revenue estimate of $97.9 million.

Notable increases in cost of goods sold, mostly related to incorporating Furoscix into the portfolio, and higher research and development expenses dinged the bottom line.

Expand

NASDAQ: MNKD

MannKind

Today’s Change

(-8.14%) $-0.28

Current Price

$3.21

Key Data Points

Market Cap

$1.1B

Day’s Range

$2.94 - $3.72

52wk Range

$2.94 - $6.51

Volume

1.6M

Avg Vol

3.9M

Gross Margin

75.18%

Oversold

I don’t think that investor reaction was justified. Furoscix is a worthy addition to the company’s product lineup, and it has a strong pipeline with several projects in the later stages of development. I wouldn’t be quite so discouraged by the numbers, and with the sell-off, I’d consider MannKind stock a bargain now.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.